Literature DB >> 23990378

Night-time symptoms and their impact on sleep in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitors: a qualitative patient interview study.

Anna Rydén1, Mona Martin, Katarina Halling, Anna Niklasson.   

Abstract

BACKGROUND: Limited data exists about night-time symptoms that are generated directly from patients with gastroesophageal reflux disease (GERD) who have a partial response to proton pump inhibitor (PPI) therapy. This information is needed to select an appropriate instrument in studies in this patient population.
OBJECTIVE: The objective of this qualitative interview study was to gain understanding of the night-time symptoms of patients with GERD who had a partial response to PPIs. The specific aims were (i) to evaluate whether GERD symptoms experienced during the night differ from those occurring during the day; and (ii) to understand the impact of night-time symptoms on sleep and next-day functioning.
METHODS: Four US sites participated in this study of patients with GERD who, despite PPI therapy for at least 4 weeks, still experienced both daytime and night-time heartburn and/or regurgitation. Non-responders to PPIs were excluded. Patient statements were coded and grouped by concept.
RESULTS: Twenty-nine patients were enrolled. The predominant and most troublesome symptoms during both the day and night were heartburn and regurgitation. At night-time only, expressions describing regurgitation were more frequent than those describing heartburn (62 vs. 26 %). During the daytime only, expressions describing regurgitation and heartburn occurred with similar frequency (21 vs. 27 %). Patients experienced greater severity of heartburn and regurgitation at night than during the day, and the difference was more pronounced for regurgitation. Patients focused on symptom frequency during the day but on symptom severity at night. Of expressions about the impact of night-time GERD symptoms, 46 % described impact on sleep and 41 % described compensatory behaviors when woken up by symptoms. Next-day impacts of night-time symptoms predominantly included changes in diet (53 %).
CONCLUSIONS: Partial responders to PPI therapy experience similar GERD symptoms at night and during the day. However, regurgitation is more predominant at night than during the day, and at night patients focus more on symptom severity than symptom frequency.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23990378     DOI: 10.1007/s40271-013-0024-1

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  32 in total

1.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-10       Impact factor: 5.725

2.  Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument.

Authors:  Donald L Patrick; Laurie B Burke; Chad J Gwaltney; Nancy Kline Leidy; Mona L Martin; Elizabeth Molsen; Lena Ring
Journal:  Value Health       Date:  2011-10-13       Impact factor: 5.725

3.  Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.

Authors:  P O Katz; F K Koch; E D Ballard; R G Bagin; T C Gautille; G C Checani; D L Hogan; V S V Pratha
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

Review 4.  The relationship between gastroesophageal reflux disease and sleep.

Authors:  Ronnie Fass
Journal:  Curr Gastroenterol Rep       Date:  2009-06

5.  The development and validation of a Nocturnal Gastro-oesophageal Reflux Disease Symptom Severity and Impact Questionnaire for adults.

Authors:  B M Spiegel; L Roberts; R Mody; G Harding; S Kothari-Talwar; P J Kahrilas; M L Camilleri; O Dabbous; D A Revicki
Journal:  Aliment Pharmacol Ther       Date:  2010-06-02       Impact factor: 8.171

Review 6.  Review article: sleep and its relationship to gastro-oesophageal reflux.

Authors:  W C Orr; R Heading; L F Johnson; M Kryger
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

Review 7.  Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease.

Authors:  G E Boeckxstaens; A Smout
Journal:  Aliment Pharmacol Ther       Date:  2010-05-18       Impact factor: 8.171

8.  The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.

Authors:  R Carlsson; J Dent; E Bolling-Sternevald; F Johnsson; O Junghard; K Lauritsen; S Riley; L Lundell
Journal:  Scand J Gastroenterol       Date:  1998-10       Impact factor: 2.423

9.  Validation of the GSFQ, a self-administered symptom frequency questionnaire for patients with gastroesophageal reflux disease.

Authors:  Pierre Paré; François Meyer; David Armstrong; Myron Pyzyk; Dan Pericak; Ron Goeree
Journal:  Can J Gastroenterol       Date:  2003-05       Impact factor: 3.522

10.  The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.

Authors:  D Armstrong; N J Talley; K Lauritsen; B Moum; T Lind; H Tunturi-Hihnala; T Venables; J Green; M A Bigard; J Mössner; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

View more
  1 in total

1.  Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo.

Authors:  David A Johnson; Anne Le Moigne; Jing Li; Charles Pollack; Peter Nagy
Journal:  Clin Drug Investig       Date:  2016-07       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.